tiprankstipranks
Trending News
More News >
Shield Therapeutics (GB:STX)
:STX
UK Market
Advertisement

Shield Therapeutics (STX) Share Forecast & Price Target

Compare
24 Followers
See the Price Targets and Ratings of:

STX Financial Forecast

STX Earnings Forecast

The previous quarter’s earnings for STX were -0.01p.
The previous quarter’s earnings for STX were -0.01p.

STX Sales Forecast

Next quarter’s sales forecast for STX is 9.46M with a range of 9.46M to 9.46M. The previous quarter’s sales results were 15.53M. STX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.66% of the time in the same period. In the last calendar year STX has Outperformed its overall industry.
Next quarter’s sales forecast for STX is 9.46M with a range of 9.46M to 9.46M. The previous quarter’s sales results were 15.53M. STX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.66% of the time in the same period. In the last calendar year STX has Outperformed its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on GB:STX
TipRanks AITipRanks
Not Ranked
TipRanks
5p
Hold
11.11%
Upside
Reiterated
07/24/25
The overall score is driven by robust technical analysis signals and positive corporate events, indicating potential for future growth. However, severe financial distress and high-risk valuation significantly dampen the overall score, highlighting substantial challenges that need to be addressed.
Stifel Nicolaus Analyst forecast on GB:STX
James OrsborneStifel Nicolaus
Stifel Nicolaus
3.5p3.8p
Hold
-15.56%
Downside
Reiterated
02/19/25
Cautious Hold Rating on Shield Therapeutics Amidst Positive Financials and Prescription Growth ConcernsWe have updated our model and reviewed our forecasts in light of Shield's 2024 trading update and review our forecasts for 2025 and beyond.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on GB:STX
TipRanks AITipRanks
Not Ranked
TipRanks
5p
Hold
11.11%
Upside
Reiterated
07/24/25
The overall score is driven by robust technical analysis signals and positive corporate events, indicating potential for future growth. However, severe financial distress and high-risk valuation significantly dampen the overall score, highlighting substantial challenges that need to be addressed.
Stifel Nicolaus Analyst forecast on GB:STX
James OrsborneStifel Nicolaus
Stifel Nicolaus
3.5p3.8p
Hold
-15.56%
Downside
Reiterated
02/19/25
Cautious Hold Rating on Shield Therapeutics Amidst Positive Financials and Prescription Growth ConcernsWe have updated our model and reviewed our forecasts in light of Shield's 2024 trading update and review our forecasts for 2025 and beyond.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

STX Analyst Recommendation Trends

Rating
Sep 24
Feb 25
May 25
Jun 25
Jul 25
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
3
4
5
7
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
4
5
7
9
In the current month, STX has received 0 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. STX average Analyst price target in the past 3 months is 2.50.
Each month's total comprises the sum of three months' worth of ratings.

STX Stock Forecast FAQ

What is GB:STX’s average 12-month price target, according to analysts?
Based on analyst ratings, Shield Therapeutics’s 12-month average price target is 2.50.
    What is GB:STX’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for GB:STX, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Shield Therapeutics a Buy, Sell or Hold?
        Shield Therapeutics has a consensus rating of Hold, which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Shield Therapeutics’s share price target?
          The average share price target for Shield Therapeutics is 2.50. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is 2.50p ,and the lowest forecast is 2.50p. The average share price target represents -44.44% Decrease from the current price of 4.5p.
            What do analysts say about Shield Therapeutics?
            Shield Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
              How can I buy shares of Shield Therapeutics?
              To buy shares of GB:STX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis